Trial Condition(s):

Anticoagulation

Patient and Physician Knowledge of Key Safety Messages

Bayer Identifier:

16167

ClinicalTrials.gov Identifier:

NCT01907048

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This cross-sectional epidemiologic study measured physician and patient awareness and understanding of the key messages in the Xarelto prescriber guide and Xarelto patient alert card.

Inclusion Criteria
- :
Physician eligibility:
 -  Prescription of rivaroxaban in the past 6 months for  adult patients for the Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (SPAF) or  Treatment of deep venous thrombosis (DVT) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT.
Patient eligibility:
 -  Use of rivaroxaban for SPAF or DVT within the previous 3 months; aged 18 years and above; able to understand and complete the consent form and patient questionnaire.
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
2227
Trial Dates
black-arrow
Phase
4
Could I receive a placebo?
No
Products
Xarelto (Rivaroxaban, BAY59-7939)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, United Kingdom

Status
Completed
 
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 
Locations

Investigative Site

Many Locations, France

Status
Completed
 
Locations

Investigative Site

Many Locations, Spain

Status
Completed
 

Trial Design